TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02311075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be performed at baseline and during endothelial stimulation by hand skin heating to quantify metabolites of NO, EETs, ET-1 and ROS

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be performed at baseline and during endothelial stimulation by hand skin heating to quantify metabolites of NO, EETs, ET-1 and ROS

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be performed at baseline and during endothelial stimulation by hand skin heating to quantify metabolites of NO, EETs, ET-1 and ROS
Study: NCT03247023

Intervention type: DEVICE
Intervention: Implantation of Integra Cadence Total Ankle Sysyem
Description: Primary Ankle Arthroplasty
Study: NCT01079260

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard ONS
Description: Standard ONS

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Energy, low volume ONS
Description: High energy, low volume ONS
Study: NCT01250717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine
Description: Taken orally three times a day for 5 days for the first part of every three week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex
Description: Given subcutaneously for 4 doses every three months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex
Description: Taken orally once a day for 6 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: after the chemo and hormonal therapy all patients have a radiacal prostatectomy
Study: NCT01789333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA Light with irradiance exposure of 9 mW/cm2
Description: The device's light emitting diode (LED) is used to deliver a metered dose of Ultraviolet A (UVA) light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.~The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 milliwatts (mW)/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin 0.1% ophthalmic solution
Description: The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed.~During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin).
Study: NCT00635362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Description: Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Description: Insertion of the LNG-IUS 4-8 weeks after cesarean delivery
Study: NCT02144311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT Scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT01559649

Intervention type: BEHAVIORAL
Intervention: Establishing Validity and Reliability
Description: Consecutive individuals admitted with suspected stroke will be recruited to participate. Individuals will undergo screening of swallowing and a videofluoroscopic swallow study within two hours. Eight screening items will be tested for validity and inter-rater reliability: 6 nonswallowing features and 2 swallowing features. Reliability in nursing observations of each screening item will be completed in all participants. Speech pathologists trained in the screening items will serve as the reference standard from which to compare reliability with registered nurses who routinely work on the hospital ward with stroke patients

Intervention type: BEHAVIORAL
Intervention: Establishing Validity and Reliability
Description: Consecutive individuals admitted with suspected stroke will be recruited to participate. Individuals will undergo screening of swallowing and a videofluoroscopic swallow study within two hours. Eight screening items will be tested for validity and inter-rater reliability: 6 nonswallowing features and 2 swallowing features. Reliability in nursing observations of each screening item will be completed in all participants. Speech pathologists trained in the screening items will serve as the reference standard from which to compare reliability with registered nurses who routinely work on the hospital ward with stroke patients
Study: NCT05397002

Intervention type: PROCEDURE
Group type: OTHER
Intervention: patient specific inverted L mandibular osteotomy modified with inferior alveolar nerve relocation
Description: preoperative CBCT was requested for virtual planning and fabrication of cutting and drilling guides. Cutting lines were outlined to be consisted of four cuts; lateral ostectomy to uncover and lateralize the inferior alveolar nerve (IAN), posterior cut run horizontally from the anterior border of the ramus to a point just above the mandibular foramen, two anterior vertical cuts run from the anterior end of the lateral ostectomy to the inferior mandibular border. The guide was removed and the osteotomy lines were completed then the mandibular setback was oriented and fixed using pre-bent plates osteosynthesis. Plane transfer was checked using CBCT and Inferior alveolar nerve function was assessed.
Study: NCT00603824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux
Description: fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if \>100 kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: argatroban or lepirudin
Description: continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range
Study: NCT04310904

Intervention type: OTHER
Intervention: contrast assessment of cardiac output (CO)
Description: Patients hospitalized in ICU will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). Patients with Swan Ganz catheter will be included as well. Cardiac output will be measured using cardiac Doppler. Simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. This solution will be injected as usual and echocardiographic imaging will be recorded. These imaging will be analyzed off-line and CO will be calculated with an algorithm previously developed and compared with the reference method. In case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.

Intervention type: OTHER
Intervention: cardiac Doppler technique
Description: Patients hospitalized in ICU will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). Patients with Swan Ganz catheter will be included as well. Cardiac output will be measured using cardiac Doppler. Simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. This solution will be injected as usual and echocardiographic imaging will be recorded. These imaging will be analyzed off-line and CO will be calculated with an algorithm previously developed and compared with the reference method. In case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.
Study: NCT00796367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: 7.5 mg phentermine and 46 mg topiramate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: 15 mg phentermine and 92 mg topiramate
Study: NCT04155567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-123
Description: TAK-123 infusion
Study: NCT01718860

Intervention type: PROCEDURE
Intervention: Quantitative measurement of neuromuscular transmission
Description: Quantitative measurement of neuromuscular transmission with train-of-four watches.
Study: NCT01140477

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accommodating Lens
Description: Accommodating lens implanted after cataract extraction
Study: NCT04400279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga group
Description: At-home yoga exercise instruction provided by a mobile/tablet app or through a computer web browser

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training group
Description: At-home HIIT exercise instruction provided by a mobile/tablet app or through a computer web browser

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination
Description: At-home yoga \& HIIT exercise instruction provided by a mobile/tablet app or through a computer web browser
Study: NCT00779142

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate intravenous 25mg/ml
Description: Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
Study: NCT03808415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG-driven
Description: The EMG signals are processed and can be visualized with visual feedback to make sure the user actively engaging throughout a therapy session.
Study: NCT02400723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: Progressive Muscle Relaxation is a treatment in which individuals tense and release their muscle groups in a sequential order. This helps reduce anxiety and tension. It also teaches individuals to differentiate between muscle tension and relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing
Description: Diaphragmatic breathing is a way in which people breathe using their diaphragm. This type of breathing has been found to promote relaxation and reduce stress.
Study: NCT04016454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention
Description: There will be one complete handover
Study: NCT00664079

Intervention type: OTHER
Intervention: Blood draws
Description: 17 mls of blood will be drawn over a 5 day period from either a central venous catheter/arterial line or with scheduled phlebotomy. The following labs will be run tT3, fT3, rT#, tT4, fT4, TSH, and tyrosine.
Study: NCT02400723

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation (Placebo)
Description: DVD-delivered psychoeducation. Participants will view videos that contain information about what anxiety is and information about one's well-being. This condition is an attention placebo control.
Study: NCT03034954

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active HD-tDCS
Description: Participants will receive active HD-tDCS at 3mA for 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tDCS
Description: Participants will receive sham HD-tDCS
Study: NCT03729336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Midstream urine collection device
Description: Non-invasive midstream urine collection device
Study: NCT02690831

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle training (IMT)
Description: Inspiratory Muscle training This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMT + Manual Therapy and Motor Control Exercise
Description: IMT + Manual Therapy and Motor Control Exercise The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powerbreathe

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Powerbreathe
Study: NCT02570802

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasonographic examination
Study: NCT02294214

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spatial Repellent product with active ingredient
Description: Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active ingredient
Description: Transfluthrin (Active ingredient)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spatial Repellent product without active ingredient (SHIELD)
Description: Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
Study: NCT03487289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: natural orifice
Description: laparoscopic right colon surgery and patients who are removed from the natural orifice and conventional will gather
Study: NCT04790630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Remediation of Executive Functioning (CCR-EF)
Description: computerized experimental brain-training treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: computerized intervention that follows recommendations for cognitive fitness
Study: NCT00310817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM conjugate vaccine, unadjuvanted

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM conjugate vaccine, unadjuvanted
Study: NCT02657304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching group
Description: patients will have a medical consultation at 2 weeks post-diagnostic and one phone call/month for duration of 5 months. The consultations will use visual support, CPAP device and its accessories.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: patients receive only usual care (standard), it's mean: diagnosis with explanation of the disease and benefit of CPAP, entrusts a medical device provider, then an appointment proposed by the doctor or taken by the patient (5 months).
Study: NCT02914873

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active surveillance
Description: Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active surveillance
Description: Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
Study: NCT02342301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing Desk
Description: Participants will be provided with a standing desk for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Desk
Description: Participants will use a traditional seated desk for 3 months
Study: NCT03385889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Spine Mobilization
Description: C1/2 graded mobilizations (Grade III/IV) provided to C1/2 segment on ipsilateral side of unilateral headache. Mobilizations will be completed for 3 sets of 30 seconds.
Study: NCT00761696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-926
Description: Oral daily dosing
Study: NCT05037019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Women diagnosed with early stage breast cancer are given a single dose of stereotactic body radiation therapy (SBRT) prior to any other treatment in the context of delayed lumpectomy due to the COVID-19 pandemic.
Study: NCT03012711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise training
Study: NCT02431559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is administered as an IV infusion over 60 ± 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is administered as an IV infusion over 60 ± 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is administered as an IV infusion over 60 ± 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is administered as an IV infusion over 60 ± 5 minutes.
Study: NCT03385889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Spine Manipulation
Description: C1/2 manipulation (Grade V) provided to C1/2 segment on ipsilateral side of unilateral headache. The goal of the manipulation technique is to elicit an audible cavitation. If no cavitation is achieved upon the first attempt, a second and final attempt will be completed. No more than two attempts will be utilized per each subject in this allocated group.
Study: NCT02431559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: PLD was administered as an IV infusion in accordance with local prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: PLD was administered as an IV infusion in accordance with local prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: PLD was administered as an IV infusion in accordance with local prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: PLD was administered as an IV infusion in accordance with local prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motolimod
Description: Motolimod was administered as an SC injection. Within 30 minutes prior to each dose of motolimod, subjects were administered 650-1000 mg acetaminophen by mouth to help mitigate potential adverse events (AEs) commonly associated with the administration of motolimod (e.g., fever, myalgia). On days with concurrent motolimod and durvalumab dosing, motolimod administration occurred 30-60 minutes after the end of the durvalumab infusion. After completion of Phase 1, a protocol amendment was implemented to remove motolimod dosing from the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motolimod
Description: Motolimod was administered as an SC injection. Within 30 minutes prior to each dose of motolimod, subjects were administered 650-1000 mg acetaminophen by mouth to help mitigate potential adverse events (AEs) commonly associated with the administration of motolimod (e.g., fever, myalgia). On days with concurrent motolimod and durvalumab dosing, motolimod administration occurred 30-60 minutes after the end of the durvalumab infusion. After completion of Phase 1, a protocol amendment was implemented to remove motolimod dosing from the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motolimod
Description: Motolimod was administered as an SC injection. Within 30 minutes prior to each dose of motolimod, subjects were administered 650-1000 mg acetaminophen by mouth to help mitigate potential adverse events (AEs) commonly associated with the administration of motolimod (e.g., fever, myalgia). On days with concurrent motolimod and durvalumab dosing, motolimod administration occurred 30-60 minutes after the end of the durvalumab infusion. After completion of Phase 1, a protocol amendment was implemented to remove motolimod dosing from the study.
Study: NCT02585089

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spanish cured-pork ham
Description: Dry-cured ham with reduced salt will be used in order to decrease the sodium intake that could affect blood pressure too. Such ham contains 25% lower salt than similar products on the market (3,7g vs 4,5g/100g).~Volunteers will receive 80g of cured pork ham daily for 28 consecutive days. They can eat the interventional product at any time of the day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cooked pork ham
Description: Volunteers will receive 100g of cooked pork ham daily for 28 consecutive days. They can eat the product (placebo product) at any time of the day.
Study: NCT02123186

Intervention type: OTHER
Intervention: newborn screening test for SMA
Description: Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
Study: NCT00663208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Capsule, Oral, Approximately 182 days from initial dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Capsule, Oral, Approximately 182 days from initial dosing
Study: NCT03729336

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Catheter for urine collection
Description: In-and-out catheter obtains urine through the urethra.
Study: NCT00426283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flovent
Description: 1760 mcg daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03422393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: On cycle 1, day 1, patients will initiate venetoclax. The dose of venetoclax will ramp-up from 20 mg PO daily to 400 mg PO daily over a 5 week period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: During the screening period, patients will continue on ibrutinib at their previous tolerated dose, unless required to stop (e.g.: by a preceding clinical trial).~On cycle 1, day 1, the dose of ibrutinib will be assigned based on the dose cohort. Patients in cohort 1 will receive ibrutinib 420 mg PO daily. Patients in cohort 2 will receive ibrutinib 560 mg PO daily. Cohort 3 will be 840 mg PO daily.
Study: NCT00842660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar (gemcitabine)
Description: Gemzar(gemcitabine) Hcl has 2'deoxy-2,2'-difluorouridine monohydrochloride
Study: NCT03451877

Intervention type: GENETIC
Group type: OTHER
Intervention: TGFB1 AND LAMA1 GENE POLYMORPHISMS
Description: we evaluated polymorphisms in the LAMA1 (rs2089760) and TGFB1 (rs4803455) genes in children younger than 13 years of age with ≥6 D myopia in an attempt to further elucidate the genetic basis of high myopia.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: TGFB1 AND LAMA1 GENE POLYMORPHISMS
Description: we evaluated polymorphisms in the LAMA1 (rs2089760) and TGFB1 (rs4803455) genes in children younger than 13 years of age with ≥6 D myopia in an attempt to further elucidate the genetic basis of high myopia.